NxStage Medical Inc. (NASDAQ:NXTM) has earned a consensus rating of “Buy” from the eight analysts that are currently covering the firm. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $25.67.

NXTM has been the subject of several recent research reports. Canaccord Genuity upped their price target on shares of NxStage Medical from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Jefferies Group increased their target price on shares of NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, August 5th. BTIG Research reiterated a “buy” rating and issued a $29.00 target price on shares of NxStage Medical in a research report on Sunday, August 7th. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research report on Tuesday, August 9th. Finally, Northland Securities set a $25.00 target price on shares of NxStage Medical and gave the company a “buy” rating in a research report on Thursday, September 15th.

In other news, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $25.97, for a total transaction of $25,970.00. Following the completion of the transaction, the president now owns 79,780 shares in the company, valued at approximately $2,071,886.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the firm’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $26.23, for a total transaction of $112,789.00. Following the transaction, the senior vice president now owns 23,041 shares of the company’s stock, valued at approximately $604,365.43. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.

Several institutional investors have recently bought and sold shares of NXTM. Principal Financial Group Inc. raised its position in NxStage Medical by 1.1% in the third quarter. Principal Financial Group Inc. now owns 14,037 shares of the medical device company’s stock valued at $351,000 after buying an additional 156 shares during the period. Menta Capital LLC raised its stake in NxStage Medical by 1.0% in the second quarter. Menta Capital LLC now owns 37,180 shares of the medical device company’s stock worth $806,000 after buying an additional 380 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in NxStage Medical by 1.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 49,876 shares of the medical device company’s stock worth $1,081,000 after buying an additional 640 shares in the last quarter. BlackRock Advisors LLC raised its stake in NxStage Medical by 1.5% in the second quarter. BlackRock Advisors LLC now owns 57,870 shares of the medical device company’s stock worth $1,255,000 after buying an additional 865 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in NxStage Medical by 2.4% in the second quarter. Nationwide Fund Advisors now owns 41,692 shares of the medical device company’s stock worth $904,000 after buying an additional 968 shares in the last quarter.

Shares of NxStage Medical (NASDAQ:NXTM) opened at 25.67 on Friday. NxStage Medical has a 52 week low of $13.49 and a 52 week high of $26.83. The company has a 50 day moving average of $24.31 and a 200 day moving average of $22.70. The firm’s market cap is $1.66 billion.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark and copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/30/nxstage-medical-inc-nxtm-receives-25-67-average-target-price-from-analysts.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.